If you want to know who really controls Sinopharm Group Co. Ltd. (HKG:1099), then you'll have to look at the makeup of its share registry. We can see that private companies own the lion's share in the company with 57% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
While institutions who own 22% came under pressure after market cap dropped to HK$53b last week,private companies took the most losses.
Let's take a closer look to see what the different types of shareholders can tell us about Sinopharm Group.
Check out our latest analysis for Sinopharm Group
SEHK:1099 Ownership Breakdown August 22nd 2022
What Does The Institutional Ownership Tell Us About Sinopharm Group?
Institutions typically measure themselves against a benchmark when reporting to their own investors, so they often become more enthusiastic about a stock once it's included in a major index. We would expect most companies to have some institutions on the register, especially if they are growing.
Sinopharm Group already has institutions on the share registry. Indeed, they own a respectable stake in the company. This implies the analysts working for those institutions have looked at the stock and they like it. But just like anyone else, they could be wrong. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Sinopharm Group's earnings history below. Of course, the future is what really matters.
SEHK:1099 Earnings and Revenue Growth August 22nd 2022
Sinopharm Group is not owned by hedge funds. China National Pharmaceutical Group Corporation is currently the company's largest shareholder with 57% of shares outstanding. With such a huge stake in the ownership, we infer that they have significant control of the future of the company. Meanwhile, the second and third largest shareholders, hold 4.7% and 2.6%, of the shares outstanding, respectively.
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. There are plenty of analysts covering the stock, so it might be worth seeing what they are forecasting, too.
Insider Ownership Of Sinopharm Group
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Most consider insider ownership a positive because it can indicate the board is well aligned with other shareholders. However, on some occasions too much power is concentrated within this group.
Our data suggests that insiders own under 1% of Sinopharm Group Co. Ltd. in their own names. We do note, however, it is possible insiders have an indirect interest through a private company or other corporate structure. It is a pretty big company, so it would be possible for board members to own a meaningful interest in the company, without owning much of a proportional interest. In this case, they own around HK$2.7m worth of shares (at current prices). It is good to see board members owning shares, but it might be worth checking if those insiders have been buying.
General Public Ownership
The general public, who are usually individual investors, hold a 21% stake in Sinopharm Group. This size of ownership, while considerable, may not be enough to change company policy if the decision is not in sync with other large shareholders.
Private Company Ownership
Our data indicates that Private Companies hold 57%, of the company's shares. Private companies may be related parties. Sometimes insiders have an interest in a public company through a holding in a private company, rather than in their own capacity as an individual. While it's hard to draw any broad stroke conclusions, it is worth noting as an area for further research.
Next Steps:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Take risks for example - Sinopharm Group has 1 warning sign we think you should be aware of.
Ultimately the future is most important. You can access this free report on analyst forecasts for the company.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
如果你想知道谁真正控制了国药控股股份有限公司(HKG:1099),那么你就得看看它的股票登记簿的构成。我们可以看到,私营公司以57%的所有权拥有该公司的最大份额。也就是说,如果股价上涨,该集团将受益最大(如果股价下跌,该集团将损失最大)。
虽然在上周市值跌至530亿港元后,持有22%股份的机构面临压力,但私营公司损失最大。
让我们仔细看看不同类型的股东能告诉我们关于国药控股的什么。
看看我们对国药控股的最新分析
联交所:1099拥有权分类2022年8月22日
关于国药控股,机构所有制告诉了我们什么?
机构通常在向自己的投资者报告时,以基准来衡量自己,因此一旦一只股票被纳入主要指数,它们往往会对这只股票变得更加热情。我们预计,大多数公司都会有一些机构登记在册,特别是在它们正在增长的情况下。
国药控股已经在股票登记处登记了机构。事实上,他们在该公司拥有可观的股份。这意味着为这些机构工作的分析师已经看过了这只股票,他们喜欢它。但就像其他人一样,他们也可能错了。如果多家机构同时改变对一只股票的看法,你可能会看到股价迅速下跌。因此,下面国药控股的收入历史值得一看。当然,未来才是真正重要的。
联交所:1099盈利及收入增长2022年8月22日
国药控股并不为对冲基金所有。中国医药集团公司目前是该公司的最大股东,持有57%的流通股。由于拥有如此巨大的股权,我们推断他们对公司的未来拥有重大控制权。与此同时,第二大和第三大股东分别持有4.7%和2.6%的流通股。
研究机构持股是衡量和筛选股票预期表现的好方法。通过研究分析师的情绪,也可以达到同样的效果。有很多分析师在追踪这只股票,所以他们的预测可能也是值得的。
国药控股的内部人所有权
不同国家对内部人的定义可能略有不同,但董事会成员总是算数的。公司管理层管理企业,但首席执行官将向董事会负责,即使他或她是董事会成员。
大多数人认为内部人持股是积极的,因为它可以表明董事会与其他股东很好地结盟。然而,在某些情况下,太多的权力集中在这个群体中。
我们的数据显示,内部人士以自己的名义持有国药控股股份有限公司不到1%的股份。然而,我们确实注意到,内部人士可能通过私人公司或其他公司结构拥有间接利益。它是一家相当大的公司,因此董事会成员有可能在该公司拥有有意义的权益,而不是拥有太多按比例分配的权益。在这种情况下,他们拥有价值约270万港元的股票(按当前价格计算)。看到董事会成员持有股票是件好事,但可能值得检查一下这些内部人士是否一直在买入。
一般公有制
通常为个人投资者的普通公众持有国药控股21%的股份。这种规模的所有权虽然可观,但如果决策与其他大股东不同步,可能不足以改变公司政策。
私营公司所有权
我们的数据显示,私营公司持有该公司57%的股份。私营公司可能是关联方。有时,内部人士通过持有一家私人公司来对上市公司感兴趣,而不是以个人身份。虽然很难得出任何大致的中风结论,但值得注意的是,这是一个值得进一步研究的领域。
接下来的步骤:
我发现看看到底是谁拥有一家公司是非常有趣的。但为了真正获得洞察力,我们还需要考虑其他信息。以风险为例-国药控股有1个警告标志我们认为你应该意识到。
最终未来是最重要的。您可以访问此免费分析师对该公司的预测报告。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。